Trial Profile
Monitoring of Immune Checkpoint Inhibitors Adverse Drug Reactions Through the WHO Vigilyze and French Pharmaco-vigilance Database (Base Nationale de Pharmacovigilance BNPV)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Jul 2021
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Avelumab (Primary) ; Durvalumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Tremelimumab (Primary)
- Indications Arthritis; Autoimmune disorders; Bladder cancer; Breast cancer; Cancer; Cardiovascular disorders; Endocrine disorders; Endometrial cancer; Gastrointestinal cancer; Glioblastoma; Hodgkin's disease; Liver cancer; Lung cancer; Malignant melanoma; Myeloma; Ovarian cancer; Pancreatic cancer; Renal cancer; Skin cancer
- Focus Adverse reactions
- Acronyms CHIMeRA
- 11 Oct 2018 Status changed from recruiting to completed.
- 13 Jul 2018 Planned End Date changed from 30 Jun 2018 to 30 Jun 2023.
- 13 Jul 2018 Planned primary completion date changed from 30 Jun 2018 to 30 Jun 2023.